

Vial Label

COMPOSITION:
Each mL contains d-
Cloprostenol (sodium salt)
75 µg

ADMINISTRATION ROUTE:
Intramuscular

WITHDRAWAL PERIOD:
NIL

Batch no
Expiry

KEEP OUT OF THE REACH
OF CHILDREN
FOR ANIMAL TREATMENT
ONLY
RESTRICTED VETERINARY
MEDICINE

GESTAVET PROST

d-Cloprostenol, solution for
injection

[20mL] [50mL]

DOSAGE
Sows: 1mL per animal
(equivalent to 75µg of d-
cloprostenol per animal)
Cows and Heifers: 2mL
per animal (equivalent to
150µg of d-cloprostenol per
animal)

Store at 2 - 8 C, protected
from light.

RVM
ACVM No A10741

HIPRA LOGO



HIPRA DETAILS

Manager (Approvals Operations)

A blue ink signature, appearing to read 'Mares Zinzley', is written over the printed name.



Leaflet

KEEP OUT OF THE REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY MEDICINE

GESTAVET PROST

d-Cloprostenol, solution for injection

[20mL][50mL]

COMPOSITION PER ML: d-Cloprostenol (sodium salt) 75 µg

d-Cloprostenol is the dextrorotatory enantiomer of cloprostenol. Various clinical studies have demonstrated that d-Cloprostenol is 3 to 4 times more potent than cloprostenol (racemic mixture). d-Cloprostenol is a functional analogue of prostaglandin F2 α with specific luteolytic activity. The administration of this product during luteal cycle phase induces regression of corpus luteum, producing preconditions for the initiation of physiological functions associated with the decrease in level of progesterone. One injection of cloprostenol during or after the 6th day of the cycle until the moment of natural luteolysis produces an immediate regression of corpus luteum. There is a refractory period of 5 to 6 days after ovulation when animals are insensitive to the luteolytic effect of prostaglandins. The mechanism of action of d-Cloprostenol in controlling ovulation is based on the induction of luteolysis and the subsequent decrease in concentration of circulating progesterone, which produces a series of hormonal and ovary events that culminates in oestrus and ovulation.

INDICATIONS:

Sows: Parturition induction at 112 - 113 days of gestation

Cows and Heifers: Induction and Synchronization of oestrus (absence of oestrus after parturition),

Cows: Chronic endometritis and pyometritis,
Luteinic cysts,
Persistent corpus luteum and
Abortion induction (from 5 to 150 days of gestation).

ADMINISTRATION ROUTE:

Intramuscular injection

DOSAGE:

Sows: 1mL per animal (equivalent to 75µg of d-cloprostenol per animal)

Cows and Heifers: 2mL per animal (equivalent to 150µg of d-cloprostenol per animal)

Induction of oestrus

Animals with a corpus luteum should receive one dose (2mL) and will display heat within 48 - 60 hours.

Synchronization of oestrus (absence of oestrus after parturition)

Administer two doses (each 2mL) 11 to 14 days apart. Heat will be displayed 48 - 60 hours after the second dose.

When used as part of a controlled breeding programme, administer one dose (2mL) of following the timing directions outlined in the programme.

Chronic endometritis and pyometritis

Administer one dose (2mL). If necessary repeat the treatment after 10 - 14 days.

Luteinic cysts

Administer one dose (2mL)

Persistent corpus luteum

Administer one dose (2mL) and inseminate at the first oestrus after injection.

If no oestrus occurs re-examine the animal and repeat the injection 11 days after the first injection. Inseminate 72 - 96 hours after the second injection.

Abortion induction (from 5 to 150 days of gestation)

Administer one dose (2mL)

INTERACTIONS:

Concomitant administration of progesterone or prostaglandin-inhibiting drugs such as NSAIDs can diminish or even annul the effect of d-Cloprostenol.

CONTRAINDICATIONS:

Pregnant animals in which abortion is not desired

Sows which have been diagnosed with foetal dystocia due to abnormal positions of the foetus, mechanical obstruction, etc

Animals with cardiovascular or respiratory diseases

Do not administer I.V.

SAFETY:

The administration of 3 times the therapeutic dose has not caused adverse effects in animals.

WITHDRAWAL PERIOD:

Meat: NIL

Milk: NIL



SPECIAL PRECAUTIONS:

The product should not be handled by pregnant women or persons with asthma or bronchial problems or other respiratory diseases

Avoid contact with the skin and eyes. In the event of accidental contact, wash the affected area with abundant water.

Store at 2 - 8 °C, protected from light. Use within 28 days of opening the pack.

Keep out of reach of children

Precautions:

Clorprostamol may damage fertility or unborn children.

May cause respiratory problems in high doses.

Do not consume for, drink or smoke when using this product. Prostaglandins may cause bronchospasm in the user.

Cloprostamol can be absorbed through the skin, avoid skin contact especially in women of child bearing age.

First Aid

In case of accidental spillage, wash immediately with water. If inhaled move to fresh air.

For Advice contact the National Poisons Centre 0800 764 766 or seek Medical Advice from a Doctor

Disposal

Dispose of contents according to label directions or in an approved landfill. Dispose of empty container in approved landfill or by approved methods.

PRESENTATION

Vials of 20 mL and 50 mL

Restricted Veterinary Medicine.

Registered pursuant to the ACVM Act, 1997 No. A10741

see www.nzfsa.govt.nz/acvm/ for registration conditions

Approved under the HSNO Act, No. HSR 002169

see www.ermanz.govt.nz for controls



HIPRA DETAILS